Lurbinectedin (API)

Lurbinectedin (API)
Product Description

Generic Name: Lurbinectedin lyophilized powder
Indication: Treatment of adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy.

Originator: Pharma Mar
Approval: US: June. 2020                   Exclusivity: FDA NCE 06/15/2025.   ODE-304 06/15/2027.

XILING LAB CO.,LTD

  • CN
  • 2017
    On CPHI since
  • 2
    Certificates
  • 50 - 99
    Employees
Company types
Generics/Biosimilars Manufacturer
Manufacturer/Innovator
Pharmaceutical company
Primary activities
Generic APIs producer
Pharmaceutical Company (generic finished products)
Specifications
  • CAS Registry Number
    497871-47-3
  • Selling Points
    International Approvals/Standards; Quality Service
  • Supplied from
    China
  • Measured In
    gram

XILING LAB CO.,LTD

  • CN
  • 2017
    On CPHI since
  • 2
    Certificates
  • 50 - 99
    Employees
Company types
Generics/Biosimilars Manufacturer
Manufacturer/Innovator
Pharmaceutical company
Primary activities
Generic APIs producer
Pharmaceutical Company (generic finished products)

More Products from XILING LAB CO.,LTD (2)

  • Eribulin Mesylate (API)

    Product Eribulin Mesylate (API)

    Generic Name: Eribulin Mesylate Injection
    Indication: Metastatic breast cancer (CN, US, EU, Japan and other countries)
    Liposarcoma (US, EU)
    Soft tissue sarcoma (Japan and other countries)

    Guidelines: 
     NCCN (2023V4), CSCO (2023), ESMO (2023) ...
  • Eribulin Mesylate Injection

    Product Eribulin Mesylate Injection

    Generic Name: Eribulin Mesylate Injection
    Indication: Metastatic breast cancer (CN, US, EU, Japan and other countries)
    Liposarcoma (US, EU)
    Soft tissue sarcoma (Japan and other countries)

    Guidelines: 
     NCCN (2023V4), CSCO (2023), ESMO (2023)

    Exc...

XILING LAB CO.,LTD resources (1)

  • Brochure Brochure-Xiling Lab's Product List

    Xiling Lab covers full chain of pharmaceutical industry with strong background and robust capabilities. We specialize in innovative XDC platform technology (especially linker-drug systems and conjugation technology) and highly complex generic products. I am writing to seek potential opportunity of becoming your supplier (both for development and commercial stage) of our excellent oncology APIs, including Lurbinectedin, Eribulin Mesylate and Trabectedin. Please kindly find our brochure for more information.